Palbociclib’s therapeutic benefits for breast cancer may be hindered by higher Ki-67 expression, primary resistance to ETs, liver metastases, multiple metastatic sites, later line of therapy, and the use of fulvestrant instead of aromatase inhibitors. Here, MKI67 is linked to breast carcinoma.